<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the uterus </plain></SENT>
<SENT sid="1" pm="."><plain>CT showed marked enlargement of the uterine body </plain></SENT>
<SENT sid="2" pm="."><plain>Chromosomal abnormalities were detected in biopsied cells, and most showed the t (8; 14) (q24; q32) translocation </plain></SENT>
<SENT sid="3" pm="."><plain>Fluorescence in situ hybridization (FISH) with a dual-color stain for IgH/C-MYC fusion showed 99% positively </plain></SENT>
<SENT sid="4" pm="."><plain>Biopsies from abdominal operation were diagnosed as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was started with intensive chemotherapy according to a protocol for Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and mature-B cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Two regimens were done with four courses with rituximab </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment response was fast, with a documented and lasting first complete remission on CT and laboratory markers after the 4 cycle treatment </plain></SENT>
</text></document>